Description
Structure & Identity
Cagri-Reta is a combination of two separate peptides rather than a single molecule. Cagrilintide acts at amylin and calcitonin receptors, while Retatrutide is engineered to activate the GLP-1, GIP, and glucagon receptors. Each retains its own structure and targets; the product simply brings both into one vial for combined research.
Research Background
Cagri-Reta research explores amylin signaling combined with triple incretin-receptor signaling.
- Combined approach. Cagri-Reta joins amylin signaling (cagrilintide) with triple GLP-1/GIP/glucagon signaling [PMID: 42744908].
- Amylin basis. The cagrilintide component rests on its development as a long-acting amylin analog [PMID: 34288673].
- Triple-agonist basis. The retatrutide component is characterized as a GLP-1/GIP/glucagon triple agonist at the receptor level[PMID: 37366315].
- Amylin class. Amylin analogs are an active metabolic-research area [PMID: 39317404].
- Receptor research. Retatrutide’s three-receptor activity is documented [PMID: 42250575].
These are research contexts, not approved uses, and the combination is intended for laboratory study.
Specifications
| Attribute | Value |
| Product type | Combination (two peptides) |
| Component 1 | Cagrilintide (amylin analog), 10 mg |
| Component 2 | Retatrutide (GLP-1/GIP/glucagon agonist), 10 mg |
| Total quantity | 20 mg per vial (10 mg + 10 mg) |
| Purity | ≥99% by reverse-phase HPLC (each component) |
| Length | 2 peptides (amylin analog + triple agonist) |
| Identity | Confirmed by ESI mass spectrometry |
| Physical form | Lyophilized powder |
| Appearance | White to off-white solid |
| Storage | -20°C, protected from light |
| Solubility | Soluble in bacteriostatic or sterile water |
| Classification | Research use only |
Storage & Handling
Store the sealed vial frozen at -20°C, shielded from light, until use. After preparing for your assay, keep the solution refrigerated at 2-8°C and study it within about two weeks. With an amylin-type peptide among the components, warming to room temperature before opening, and minimal freeze-thaw cycles all help protect the material.
Quality Assurance
The components of Cagri-Reta are produced under research-grade manufacturing controls and verified by an independent lab before release. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with testing carried out by third-party laboratories such as Janoshik Analytical along with domestic US labs. A certificate of analysis accompanies each batch, so the results trace to the vial you receive.
Frequently Asked Questions
What is Cagri-Reta?
Cagri-Reta is a combination research product containing cagrilintide (an amylin analog) and Retatrutide (a triple GLP-1/GIP/glucagon receptor agonist), 10 mg of each. It is studied in metabolic research and supplied for research use only.
Why combine cagrilintide with Retatrutide?
It brings together amylin signaling and triple incretin-receptor signaling in one preparation, letting researchers study the two complementary approaches side by side.
Are the two peptides fused together?
No, they are two separate molecules combined in a single vial, each with its own structure and receptor targets. Cagri-Reta is a mixture, not a single fused peptide.
How much of each peptide is in the vial?
There is 10 mg of cagrilintide and 10 mg of Retatrutide, for 20 mg of peptide total.
Is Cagri-Reta FDA approved?
No, neither component combination is FDA approved. The material here is a research-use-only preparation, not for human or veterinary use.
How should Cagri-Reta be stored?
Keep the powder frozen at -20°C and protected from light until use. As with all lyophilized peptides, preparation and post-preparation handling should follow your lab’s own protocols
How are both components verified?
Each is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch ships with a certificate of analysis.
